Yaz is a birth control pill that has been linked to serious health risks. Preceded by Bayer’s Yasmin, the Food and Drug Administration (FDA) approved Yaz in 2006. Both pills rely on estrogen and a progestin called drospirenone to prevent pregnancy. The pills are also approved to lessen symptoms of pre-menstrual dysphoric disorder (PMDD).
However, Yaz and other oral contraceptives containing drospirenone have been linked to significant injuries and fatalities resulting from blood clots, or deep vein thrombosis (DVT), even in otherwise healthy, young women. Depending on where a blood clot travels in the body, it could result in:
- Pulmonary Embolism (PE) – clot in the lungs
- Stroke – clot in the brain
- Heart Attack – clot in the heart
- Death – pulmonary embolisms, strokes and heart attack can all prove deadly.
Touted by Bayer as a miracle pill, Yaz hit the ground running after its 2006 approval. This was largely due to misleading commercials that failed to warn of the drug’s risks and overstated its effectiveness. The ads also made it seem as though the pill was approved to treat PMS and acne – which it was not.
The FDA and state attorneys put a stop to Bayer’s deceitful Yaz ad campaign and forced Bayer to run a $20-million corrective campaign, but the original ads had already made an impact on millions of women. Within two years of approval, Yaz had cornered 18% of the market for oral contraceptives.
FDA Safety Warnings Regarding Yaz
The FDA issued a Safety Announcement regarding Yaz-related blood clot risks in May 2011, citing two studies that showed two- to three-fold increased riskfor women taking drospirenone-containing pills, compared to women taking other contraceptives. This dangerous risk exists for all women who take Yaz or Yasmin, even those who are in otherwise great health.
In December 2011, the FDA put together a panel of experts to discuss the benefits versus the risks of Yaz. Although the committee voted to allow Yaz, and related products, to stay on the market, it mandated an immediate label change. The label change was required to show the increased risk for blood clots and related issues so that women who receive new prescriptions of Yaz will be warned.
In a shocking turn of events, allegations of corruption in the Yaz review committee surfaced not long afterwards. Four women’s advocacy groups sent a joint letter to the FDA pointing out that members of the panel had recent financial ties to Yaz and Yasmin manufacturer Bayer. Despite this clear conflict of interest, the FDA stood by the committee’s decision to allow Yaz to remain on the market. As more and more women and families of women who have died after taking Yaz file injury lawsuits, this decision is clearly questionable
Thousands of Yaz Lawsuits Filed
More than 11,300 women from across the country have filed suits against Bayer after suffering blood clots and related injuries as a result of Yaz. By filing claims, these women, and their families, are eligible to receive compensation for their suffering, which covers the costs of medical bills, future treatment, lost income, and associated physical and emotional burdens. Bayer has paid out $142 million to settle approximately 650 Yaz cases. This averages to nearly $220,000 per woman.
If you took Yaz or Yasmin and suffered as these women did, you too deserve compensation. When these women and their families stand up for their rights, they send a clear message to Bayer that manufacturing a dangerous pill and not warning patients is unacceptable. The consequences may prevent future harm to consumers by convincing Bayer, and other drug companies, to refrain from the same behavior.
If you or a loved one suffered a blot clot or related health issue while taking Yaz or Yasmin, contact Heygood, Orr & Pearson today to find out if you are eligible for compensation. Speak to one of our experienced attorneys to determine the best way to protect your legal rights. We will work with you on a contingency fee basis, meaning you pay nothing until we obtain compensation on your behalf.